These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2565404)

  • 1. Increased cytosolic pH in multidrug-resistant human lung tumor cells: effect of verapamil.
    Keizer HG; Joenje H
    J Natl Cancer Inst; 1989 May; 81(9):706-9. PubMed ID: 2565404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
    Schuurhuis GJ; van Heijningen TH; Cervantes A; Pinedo HM; de Lange JH; Keizer HG; Broxterman HJ; Baak JP; Lankelma J
    Br J Cancer; 1993 Nov; 68(5):898-908. PubMed ID: 8105865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin.
    Sadasivan R; Morgan R; Fabian C; Stephens R
    Cancer Lett; 1991 May; 57(2):165-71. PubMed ID: 1673873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.
    Spoelstra EC; Westerhoff HV; Pinedo HM; Dekker H; Lankelma J
    Eur J Biochem; 1994 Apr; 221(1):363-73. PubMed ID: 7909520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein.
    Roepe PD; Wei LY; Cruz J; Carlson D
    Biochemistry; 1993 Oct; 32(41):11042-56. PubMed ID: 8105888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
    Naito M; Tsuge H; Kuroko C; Koyama T; Tomida A; Tatsuta T; Heike Y; Tsuruo T
    J Natl Cancer Inst; 1993 Feb; 85(4):311-6. PubMed ID: 7678867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of doxorubicin-resistant Lewis lung carcinoma variants.
    Bruno NA; Carver LA; Slate DL
    Cancer Commun; 1990; 2(4):151-8. PubMed ID: 1973357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
    Nygren P; Larsson R; Gruber A; Peterson C; Bergh J
    Br J Cancer; 1991 Dec; 64(6):1011-8. PubMed ID: 1684906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of multiple drug resistance in human bladder cancer cell lines.
    Shinohara N; Liebert M; Wedemeyer G; Chang JH; Grossman HB
    J Urol; 1993 Aug; 150(2 Pt 1):505-9. PubMed ID: 8100862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells.
    Pereira E; Borrel MN; Fiallo M; Garnier-Suillerot A
    Biochim Biophys Acta; 1994 Jan; 1225(2):209-16. PubMed ID: 7904185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycolysis in P-glycoprotein-overexpressing human tumor cell lines. Effects of resistance-modifying agents.
    Broxterman HJ; Pinedo HM; Kuiper CM; Schuurhuis GJ; Lankelma J
    FEBS Lett; 1989 Apr; 247(2):405-10. PubMed ID: 2565823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro.
    Hill BT; van der Graaf WT; Hosking LK; de Vries EG; Mulder NH; Whelan RD
    Int J Cancer; 1993 Sep; 55(2):330-7. PubMed ID: 8103761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
    Coley HM; Workman P; Twentyman PR
    Br J Cancer; 1991 Mar; 63(3):351-7. PubMed ID: 1672252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein expression in bladder cancer.
    Park J; Shinohara N; Liebert M; Noto L; Flint A; Grossman HB
    J Urol; 1994 Jan; 151(1):43-6. PubMed ID: 7902877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.
    Huet S; Schott B; Robert J
    Br J Cancer; 1992 Apr; 65(4):538-44. PubMed ID: 1348623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies.
    Merlin JL; Guerci A; Marchal S; Missoum N; Ramacci C; Humbert JC; Tsuruo T; Guerci O
    Blood; 1994 Jul; 84(1):262-9. PubMed ID: 7912556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verapamil enhances doxorubicin activity in cultured human renal carcinoma cells.
    Lai T; Collins CM; Hall P; Morgan AP; Smith PJ; Stonebridge BR; Symes MO
    Eur J Cancer; 1993; 29A(3):378-83. PubMed ID: 8104443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein.
    Roepe PD
    Biochemistry; 1992 Dec; 31(50):12555-64. PubMed ID: 1361758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential modulation of P-glycoprotein transport by protein kinase inhibition.
    Bates SE; Lee JS; Dickstein B; Spolyar M; Fojo AT
    Biochemistry; 1993 Sep; 32(35):9156-64. PubMed ID: 7690250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.
    Schuurhuis GJ; Broxterman HJ; Cervantes A; van Heijningen TH; de Lange JH; Baak JP; Pinedo HM; Lankelma J
    J Natl Cancer Inst; 1989 Dec; 81(24):1887-92. PubMed ID: 2574239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.